First-round funding for eye technology firm HyperBranch
This article was originally published in Clinica
HyperBranch Medical Technology, a Raleigh, North Carolina-based developer of eye surgery products, has raised $6m in a first round of venture capital financing. The funds, contributed by The Aurora Funds (Durham, North Carolina) and HIG Ventures (Miami, Florida), will help the company carry out preclinical and clinical development of its two lead products, a synthetic lens for use in cataract surgery and wound-sealing glue for use in ophthalmics.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.